NO20051900L - Kinazolinderivater som SRC tyrosin kinase inhibitorer - Google Patents

Kinazolinderivater som SRC tyrosin kinase inhibitorer

Info

Publication number
NO20051900L
NO20051900L NO20051900A NO20051900A NO20051900L NO 20051900 L NO20051900 L NO 20051900L NO 20051900 A NO20051900 A NO 20051900A NO 20051900 A NO20051900 A NO 20051900A NO 20051900 L NO20051900 L NO 20051900L
Authority
NO
Norway
Prior art keywords
group
quinazoline derivatives
tyrosine kinase
kinase inhibitors
src tyrosine
Prior art date
Application number
NO20051900A
Other languages
English (en)
Other versions
NO331951B1 (no
Inventor
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20051900L publication Critical patent/NO20051900L/no
Publication of NO331951B1 publication Critical patent/NO331951B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen angår kinazolinderivater med formel I, hvor Z er O-, S-, SO-, S02-, N(R2)- eller C(R2)2-gruppe hvor hver R2-gruppe er hydrogen eller (1-8C)alkyl, m er 0, 1, 2 eller 3, hver R1-gruppe er valgt fra halogen, (1-8C)alkyl, (1-6C)alkoksy og hvilken som helst av de andre betydninger definert i be skrivelsen, n er 0, 1, 2 eller 3 og hver R 3-gruppe er valgt fra halogen, (1-8C)alkyl, (1-6C)alkoksy og hvilken som helst av de andre betydninger definert i beskrivelsen, eller farmasøytisk akseptable salter derav, fremgangsmåter for deres fremstilling, farmasøytiske preparater inneholdende dem og anvendelse av dem ved fremstilling av et medikament for anvendelse som et anti-invasivt middel ved begrensning og/eller behandling av fast tumor-sykdom.
NO20051900A 2002-11-04 2005-04-19 Kinazolinderivater, farmasoytisk preparat inneholdende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom NO331951B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02292736 2002-11-04
EP03290900 2003-04-10
PCT/GB2003/004703 WO2004041829A1 (en) 2002-11-04 2003-10-29 Quinazoline derivatives as src tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20051900L true NO20051900L (no) 2005-06-01
NO331951B1 NO331951B1 (no) 2012-05-14

Family

ID=32313852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051900A NO331951B1 (no) 2002-11-04 2005-04-19 Kinazolinderivater, farmasoytisk preparat inneholdende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom

Country Status (28)

Country Link
US (1) US7462623B2 (no)
EP (1) EP1562955B1 (no)
JP (2) JP4593464B2 (no)
KR (1) KR101089462B1 (no)
AR (1) AR041884A1 (no)
AT (1) ATE387451T1 (no)
AU (1) AU2003278383B2 (no)
BR (1) BR0315756A (no)
CA (1) CA2503371C (no)
CO (1) CO5560578A2 (no)
CY (1) CY1108061T1 (no)
DE (1) DE60319410T2 (no)
DK (1) DK1562955T3 (no)
EG (1) EG24957A (no)
ES (1) ES2300619T3 (no)
HK (1) HK1079195A1 (no)
IL (1) IL168013A (no)
IS (1) IS2568B (no)
MX (1) MXPA05004858A (no)
MY (1) MY137835A (no)
NO (1) NO331951B1 (no)
NZ (1) NZ539408A (no)
PL (1) PL215161B1 (no)
PT (1) PT1562955E (no)
RU (1) RU2350618C2 (no)
SI (1) SI1562955T1 (no)
TW (1) TWI320786B (no)
WO (1) WO2004041829A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
CA2995880C (en) 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2020055755A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6809097B1 (en) * 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
UA72749C2 (en) 1998-09-29 2005-04-15 White Holdings Corp Substituted 3-cyanoquinolines, a method for the preparation thereof (variants), pharmaceutical composition based thereon, a method for the treatment, inhibiting the growth or elimination of neoplasms and a method for the treatment, inhibiting progressing or elimination of polycystic kidney disease using them
ATE294796T1 (de) * 1998-10-08 2005-05-15 Astrazeneca Ab Chinazolin derivate
CZ303692B6 (cs) * 1999-02-10 2013-03-13 Astrazeneca Ab Chinazolinové deriváty jako inhibitory angiogeneze
EP1218356A1 (en) 1999-09-21 2002-07-03 AstraZeneca AB Quinazoline compounds and pharmaceutical compositions containing them
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
IL149034A0 (en) 1999-11-05 2002-11-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
ATE300303T1 (de) 2000-03-06 2005-08-15 Astrazeneca Ab Verwendung von quinazolinderivate als inhibitoren der angiogenese
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
KR100858069B1 (ko) 2000-04-07 2008-09-22 아스트라제네카 아베 퀴나졸린 화합물류
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2001279938B2 (en) 2000-08-09 2007-01-25 Astrazeneca Ab Indole, azaindole and indazole derivatives having VEGF inhibiting activity
BR0113056A (pt) 2000-08-09 2003-07-08 Astrazeneca Ab Composto, processo papa a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, e, uso de um composto
US6887874B2 (en) * 2000-08-09 2005-05-03 Astrazeneca Ab Cinnoline compounds
PL202812B1 (pl) 2000-08-21 2009-07-31 Astrazeneca Ab Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
WO2002030926A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives
AU2001292138A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
EP1332141A1 (en) 2000-10-25 2003-08-06 AstraZeneca AB Quinazoline derivatives
EP1381599B1 (en) 2001-04-19 2008-09-24 Astrazeneca AB Quinazoline derivatives
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
JP4326328B2 (ja) 2001-07-16 2009-09-02 アストラゼネカ アクチボラグ キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
WO2003047582A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives as antitumour agents
US7268230B2 (en) * 2002-02-01 2007-09-11 Astrazeneca Ab Quinazoline compounds
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
WO2004004732A1 (en) 2002-07-09 2004-01-15 Astrazeneca Ab Quinazoline derivatives for use in the treatment of cancer
JP2006502132A (ja) 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 癌の治療における血管内皮細胞増殖因子受容体の阻害薬ｚｄ６４７４と放射線療法との併用
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
CA2514227C (en) 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Also Published As

Publication number Publication date
JP2006506463A (ja) 2006-02-23
PL376255A1 (en) 2005-12-27
PT1562955E (pt) 2008-05-05
US20060122199A1 (en) 2006-06-08
CA2503371A1 (en) 2004-05-21
TW200420567A (en) 2004-10-16
SI1562955T1 (sl) 2008-06-30
TWI320786B (en) 2010-02-21
MY137835A (en) 2009-03-31
ATE387451T1 (de) 2008-03-15
MXPA05004858A (es) 2005-07-22
JP4593464B2 (ja) 2010-12-08
RU2005117337A (ru) 2006-01-20
JP2010270143A (ja) 2010-12-02
BR0315756A (pt) 2005-09-06
AU2003278383A1 (en) 2004-06-07
EG24957A (en) 2011-02-28
EP1562955A1 (en) 2005-08-17
NZ539408A (en) 2007-09-28
DE60319410T2 (de) 2009-02-19
AR041884A1 (es) 2005-06-01
DE60319410D1 (en) 2008-04-10
AU2003278383B2 (en) 2007-06-14
ES2300619T3 (es) 2008-06-16
US7462623B2 (en) 2008-12-09
WO2004041829A1 (en) 2004-05-21
CO5560578A2 (es) 2005-09-30
DK1562955T3 (da) 2008-06-02
HK1079195A1 (en) 2006-03-31
RU2350618C2 (ru) 2009-03-27
IS7849A (is) 2005-05-19
CA2503371C (en) 2011-01-11
KR20050074526A (ko) 2005-07-18
EP1562955B1 (en) 2008-02-27
KR101089462B1 (ko) 2011-12-07
IL168013A (en) 2013-03-24
NO331951B1 (no) 2012-05-14
IS2568B (is) 2010-01-15
PL215161B1 (pl) 2013-10-31
CY1108061T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
NO20051900L (no) Kinazolinderivater som SRC tyrosin kinase inhibitorer
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20061743L (no) Kinazolinderivater
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
NO20051010L (no) Triazolderivater som transformerende vekst faktor (TGF) inhibitorer
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20054842L (no) Kjemiske forbindelser
NO20071703L (no) Kinazolinderivater
NO20072259L (no) Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20061746L (no) Kinazolinderivater som antiproliferative midler
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
NO20063382L (no) Nye kinolinderivater
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
NO20061415L (no) Kinazolinderivater
NO20083059L (no) Pyrimidinderivater
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
ATE341545T1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
BRPI0512588A (pt) derivados de uréia de pirimidina como inibidores de cinase
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
HUP0202490A2 (hu) Indazolszármazékok és ezeket tartalmazó protein-kináz gátló hatású gyógyszerkészítmények
NO20082730L (no) Morfolinopyrimidinderivater og deres anvendelse i terapi
NO20090328L (no) Nye forbindelser 385

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees